Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models

Mostrar otras versiones (1)

Daily vs. weekly dosing with EGFR inhibitors (gefitinib and lapatinib) and an AKT inhibitor (MK2206) were compared in two rodent breast cancer models. Female Sprague-Dawley rats were administered methylnitrosourea (MNU) at 50 days of age, and gefitinib (daily/weekly dosing at 10/70 mg/kg BW) or lapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lubet, Ronald A., Steele, Vernon E., Juliana, M.M., Bode, Ann, Moeinpour, Fariba, Grubbs, Clinton J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072405/
https://www.ncbi.nlm.nih.gov/pubmed/29565450
http://dx.doi.org/10.3892/or.2018.6313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072405/
https://www.ncbi.nlm.nih.gov/pubmed/29565450
http://dx.doi.org/10.3892/or.2018.6313

Ejemplares similares